

# Muthiah Vaduganathan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7604998/publications.pdf>

Version: 2024-02-01

340  
papers

14,293  
citations

39113

52  
h-index

31191

106  
g-index

345  
all docs

345  
docs citations

345  
times ranked

19494  
citing authors

#	ARTICLE	IF	CITATIONS
1	Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 165-178.	1.4	40
2	Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 191-201.	0.7	6
3	Trends in hospitalizations for heart failure, acute myocardial infarction, and stroke in the United States from 2004 to 2018. <i>American Heart Journal</i> , 2022, 243, 103-109.	1.2	24
4	Contemporary Nationwide Heart Transplantation and Left Ventricular Assist Device Outcomes in Patients with Histories of Bariatric Surgery. <i>Journal of Cardiac Failure</i> , 2022, 28, 330-333.	0.7	6
5	Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia. <i>European Journal of Heart Failure</i> , 2022, 24, 169-180.	2.9	23
6	Cost and Value in Contemporary Heart Failure Clinical Guidance Documents. <i>JACC: Heart Failure</i> , 2022, 10, 1-11.	1.9	11
7	Prognosis for patients with heart failure and reduced ejection fraction with and without diabetes: A 7-year nationwide veteran administration analysis. <i>International Journal of Cardiology</i> , 2022, 346, 30-34.	0.8	4
8	Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 554-563.	0.7	4
9	Physician Practice Pattern Variations in Common Clinical Scenarios Within 5 US Metropolitan Areas. <i>JAMA Health Forum</i> , 2022, 3, e214698.	1.0	7
10	Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018. <i>ESC Heart Failure</i> , 2022, 9, 947-952.	1.4	15
11	Natriuretic peptide-based inclusion criteria in heart failure with preserved ejection fraction clinical trials: insights from <scp>PARAGON-HF</scp>. <i>European Journal of Heart Failure</i> , 2022, 24, 672-677.	2.9	6
12	Rates of Spironolactone Initiation and Subsequent Hyperkalemia Hospitalizations in Patients with Heart Failure with Preserved Ejection Fraction Following the TOPCAT trial: A Cohort Study of Medicare Beneficiaries. <i>Journal of Cardiac Failure</i> , 2022, 28, 1035-1039.	0.7	5
13	<scp>Angiotensin-â€ˆneprilysin</scp> inhibition and renal outcomes across the spectrum of ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 1591-1598.	2.9	14
14	Robustness of outcomes in trials evaluating sodium-â€ˆglucose co-â€ˆtransporter 2 inhibitors for heart failure. <i>ESC Heart Failure</i> , 2022, , .	1.4	4
15	Prevalence and Prognostic Significance of Polyvascular Disease in Patients Hospitalized With Acute Decompensated Heart Failure: The ARIC Study. <i>Journal of Cardiac Failure</i> , 2022, 28, 1267-1277.	0.7	3
16	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	1.2	23
17	Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin. <i>Journal of the American College of Cardiology</i> , 2022, 79, 432-444.	1.2	21
18	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2022, 79, 504-510.	1.2	21

#	ARTICLE	IF	CITATIONS
19	Association of readmission penalty amount with subsequent 30-day risk standardized readmission and mortality rates among patients hospitalized with heart failure: An analysis of get with the guidelines “ heart failure participating centers. American Heart Journal, 2022, 246, 1-11.	1.2	0
20	A Heart Team approach to contemporary device decision-making in heart failure. European Journal of Heart Failure, 2022, 24, 562-564.	2.9	1
21	Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from <sc>PARAGON-HF</sc>. European Journal of Heart Failure, 2022, 24, 794-803.	2.9	15
22	Dronedarone for the Treatment of Atrial Fibrillation with Concomitant Heart Failure with Preserved and Mildly Reduced Ejection Fraction: Post-Hoc Analysis of the ATHENA Trial. European Journal of Heart Failure, 2022, , .	2.9	17
23	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. JACC: Heart Failure, 2022, 10, 184-197.	1.9	75
24	Implementation of Cardiometabolic Centers and Training Programs. Current Diabetes Reports, 2022, , 1.	1.7	0
25	Optimizing Foundational Therapies in Patients With HF rEF. JACC Basic To Translational Science, 2022, 7, 504-517.	1.9	47
26	Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 2022, 24, 861-866.	2.9	7
27	Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States. Circulation: Heart Failure, 2022, 15, CIRCHEARTFAILURE121009099.	1.6	14
28	The Relationship Between Atrial Fibrillation, Mitral Regurgitation, and Heart Failure Subtype: The ARIC Study. Journal of Cardiac Failure, 2022, 28, 883-892.	0.7	7
29	Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, E12-E14.	1.4	5
30	Accelerated and personalized therapy for heart failure with reduced ejection fraction. European Heart Journal, 2022, 43, 2573-2587.	1.0	41
31	Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials. JAMA Cardiology, 2022, 7, 540.	3.0	20
32	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation, 2022, 146, 438-449.	1.6	53
33	Association of Baseline and Longitudinal Changes in Frailty Burden and Risk of Heart Failure in Type 2 Diabetes—Findings from the Look AHEAD Trial. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 2489-2497.	1.7	9
34	Estimating the Benefits of Combination Medical Therapy in Heart Failure With Mildly Reduced and Preserved Ejection Fraction. Circulation, 2022, 145, 1741-1743.	1.6	17
35	Health Status Trajectories Before and After Hospitalization for Heart Failure. Circulation, 2022, 145, 1872-1874.	1.6	11
36	Validation of the WATCH-DM and TRS-HF <sub>DM</sub> Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort Analysis. Journal of the American Heart Association, 2022, 11, .	1.6	10

#	ARTICLE	IF	CITATIONS
37	Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction. <i>Clinical Cardiology</i> , 2022, 45, .	0.7	2
38	Diabetes Care Among Older Adults Enrolled in Medicare Advantage Versus Traditional Medicare Fee-For-Service Plans: The Diabetes Collaborative Registry. <i>Diabetes Care</i> , 2022, 45, 1549-1557.	4.3	6
39	Trends in Utilization and Cost of Low-Density Lipoprotein Cholesterol-Lowering Therapies Among Medicare Beneficiaries. <i>JAMA Cardiology</i> , 2021, 6, 92-96.	3.0	10
40	Cardiologist Evaluation of Patients With Type 2 Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007440.	0.9	16
41	Prevention of heart failure events with intensive versus standard blood pressure lowering across the spectrum of kidney function and albuminuria: a SPRINT substudy. <i>European Journal of Heart Failure</i> , 2021, 23, 384-392.	2.9	19
42	Trends in Female Authorship: A Bibliometric Analysis of The Annals of Thoracic Surgery. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1387-1393.	0.7	23
43	Temporal trends in risk profiles among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2021, 232, 154-163.	1.2	8
44	Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials. <i>ESC Heart Failure</i> , 2021, 8, 26-36.	1.4	6
45	Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice. <i>JAMA Cardiology</i> , 2021, 6, 267.	3.0	22
46	Association of Medicaid Expansion With Rates of Utilization of Cardiovascular Therapies Among Medicaid Beneficiaries Between 2011 and 2018. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007492.	0.9	13
47	Treatment of HF in an Era of Multiple Therapies. <i>JACC: Heart Failure</i> , 2021, 9, 1-12.	1.9	26
48	Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. <i>JACC: Heart Failure</i> , 2021, 9, 65-73.	1.9	93
49	Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults With Diabetes. <i>JAMA Cardiology</i> , 2021, 6, 354.	3.0	15
50	Prevalence and Prognostic Significance of Mitral Regurgitation in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 179-189.	1.9	21
51	Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches. <i>Heart Failure Reviews</i> , 2021, 26, 11-21.	1.7	1
52	Clinical Outcomes in Young US Adults Hospitalized With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 379.	2.6	165
53	Intensive blood pressure control appears to be effective and safe in patients with peripheral artery disease: the Systolic Blood Pressure Intervention Trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e38-e40.	1.4	3
54	Considering dose in pharmacological therapies for heart failure – Authors' reply. <i>Lancet</i> , The, 2021, 397, 275.	6.3	0

#	ARTICLE	IF	CITATIONS
55	Racial Differences and Temporal Obesity Trends in Heart Failure with Preserved Ejection Fraction. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1309-1318.	1.3	4
56	<scp>OUTSTEPâ€HF</scp>: reâ€evaluating the role of physical activity measures in drug and device development in heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 136-139.	2.9	2
57	Physician Density by Specialty Type in Urban and Rural Counties in the US, 2010 to 2017. <i>JAMA Network Open</i> , 2021, 4, e2033994.	2.8	36
58	Trends, Management, and Outcomes of Acute Myocardial Infarction Hospitalizations With Inâ€Hospitalâ€Onset Versus Outâ€ofâ€Hospital Onset: The ARIC Study. <i>Journal of the American Heart Association</i> , 2021, 10, e018414.	1.6	7
59	Patient Characteristics and Clinical Outcomes of Type 1 Versus Type 2 Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 848-857.	1.2	50
60	Neprilysin and Corin. <i>JACC: Heart Failure</i> , 2021, 9, 96-99.	1.9	1
61	Addressing Equity and More in 2021. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1372-1373.	1.2	0
62	Prevention of heart failure events with sodiumâ€glucose coâ€transporter 2 inhibitors across a spectrum of cardioâ€renalâ€metabolic risk. <i>European Journal of Heart Failure</i> , 2021, 23, 1002-1008.	2.9	25
63	Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials. <i>Circulation</i> , 2021, 143, 949-958.	1.6	15
64	Development and validation of optimal phenomapping methods to estimate long-term atherosclerotic cardiovascular disease risk in patients with type 2 diabetes. <i>Diabetologia</i> , 2021, 64, 1583-1594.	2.9	13
65	Dynamic changes in cardiovascular and systemic parameters prior to sudden cardiac death in heart failure with reduced ejection fraction: a <scp>PARADIGMâ€HF</scp> analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 1346-1356.	2.9	11
66	Biomarker-Based Risk Prediction of Incident Heartâ€Failure in Pre-Diabetes andâ€Diabetes. <i>JACC: Heart Failure</i> , 2021, 9, 215-223.	1.9	50
67	Virtual optimization of guidelineâ€directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENTâ€HF pilot study. <i>European Journal of Heart Failure</i> , 2021, 23, 1191-1201.	2.9	45
68	Editorial Expression of Concern: Water and sodium in heart failure: a spotlight on congestion. <i>Heart Failure Reviews</i> , 2021, 26, 1529-1529.	1.7	1
69	Incidence and Outcomes of Pneumonia in Patients With Heartâ€Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1961-1973.	1.2	35
70	Worsening Heartâ€Failure Episodes Outside a Hospital Setting in Heartâ€Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 374-382.	1.9	23
71	Dual Antiplatelet Therapy Versus Aspirin in Patients With Stroke or Transient Ischemic Attack: Meta-Analysis of Randomized Controlled Trials. <i>Stroke</i> , 2021, 52, e217-e223.	1.0	31
72	Prescription Filling Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States. <i>Journal of Cardiac Failure</i> , 2021, 27, 1280-1284.	0.7	7

#	ARTICLE	IF	CITATIONS
73	Effect of government-issued state of emergency and reopening orders on cardiovascular hospitalizations during the COVID-19 pandemic. <i>American Journal of Preventive Cardiology</i> , 2021, 6, 100172.	1.3	5
74	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (<sc>US</sc>, <sc>UK</sc> and Sweden). <i>European Journal of Heart Failure</i> , 2021, 23, 1499-1511.	2.9	80
75	Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2608-2616.	1.4	8
76	Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients. <i>Journal of General Internal Medicine</i> , 2021, 36, 2532-2535.	1.3	29
77	Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the <sc>PARADIGM-HF</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1518-1524.	2.9	20
78	Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care. <i>Heart</i> , 2021, 107, 1407-1416.	1.2	16
79	Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map. <i>European Journal of Heart Failure</i> , 2021, 23, 1468-1476.	2.9	29
80	Prognostic Value of Natriuretic Peptides and Cardiac Troponins in COVID-19. <i>Circulation</i> , 2021, 144, 177-179.	1.6	20
81	Kidney Function and Outcomes in Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 330-343.	1.2	90
82	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021, 237, 45-53.	1.2	3
83	Hospitalization of Patients With (But Not for) Heart Failure: An Opportunity for Accelerated Guideline-Directed Medical Therapy Optimization?. <i>Journal of Cardiac Failure</i> , 2021, 27, 910-912.	0.7	1
84	Clinical and Echocardiographic Characteristics of Patients Hospitalized With Acute Versus Chronic Heart Failure With Preserved Ejection Fraction (From the ARIC Study). <i>American Journal of Cardiology</i> , 2021, 158, 59-65.	0.7	1
85	Cardiovascular and Kidney Outcomes Across the Glycemic Spectrum. <i>Journal of the American College of Cardiology</i> , 2021, 78, 453-464.	1.2	45
86	Marijuana Use and In-Hospital Outcomes After Percutaneous Coronary Intervention in Michigan, United States. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1757-1767.	1.1	3
87	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the <sc>EMPA-REG OUTCOME</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2775-2784.	2.2	12
88	The Intersection of Type 2 Myocardial Infarction and Heart Failure. <i>Journal of the American Heart Association</i> , 2021, 10, e020849.	1.6	2
89	Potential Implications of Expanded US Food and Drug Administration Labeling for Sacubitril/Valsartan in the US. <i>JAMA Cardiology</i> , 2021, 6, 1415.	3.0	19
90	Treatment Effects of Sacubitril/Valsartan Compared With Valsartan by Ejection Fraction in Patients With Recent Hospitalization. <i>Journal of Cardiac Failure</i> , 2021, 27, 1027-1030.	0.7	0

#	ARTICLE	IF	CITATIONS
91	Asymptomatic Diabetic Cardiomyopathy: an Underrecognized Entity in Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 41.	1.7	15
92	Gender Differences in Medicare Payments Among Cardiologists. <i>JAMA Cardiology</i> , 2021, 6, 1432.	3.0	6
93	Potential implications of the FDA approval of semaglutide for overweight and obese adults in the United States. <i>Progress in Cardiovascular Diseases</i> , 2021, 68, 97-98.	1.6	6
94	Hospitalizations and Outcomes of T1MI Observed Before and After the Introduction of MI Subtype Codes. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1242-1253.	1.2	7
95	Modifiable Risk Factor Burden Among 3 Different Age Groups with Heart Failure. <i>American Journal of Cardiology</i> , 2021, 156, 150-152.	0.7	0
96	Contemporary Burden of Primary Versus Secondary Heart Failure Hospitalizations in the United States. <i>American Journal of Cardiology</i> , 2021, 156, 140-142.	0.7	4
97	Patterns of Use and Clinical Outcomes with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Heart Failure and Changes in Kidney Function: An Analysis of the Veteransâ€™ Health Administrative Database. <i>CardioRenal Medicine</i> , 2021, 11, 226-236.	0.7	5
98	Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date. <i>International Journal of Cardiology</i> , 2021, 323, 188-191.	0.8	7
99	Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1635-1654.	1.2	42
100	Prevalence and Prognostic Implications of Diabetes With Cardiomyopathy in Community-Dwelling Adults. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1587-1598.	1.2	23
101	Serum Potassium and Mortality in High-Risk Patients: SPRINT. <i>Hypertension</i> , 2021, 78, 1586-1594.	1.3	3
102	Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance. <i>Circulation: Heart Failure</i> , 2021, , CIRCHEARTFAILURE121008403.	1.6	1
103	In-Hospital Initiation of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2004-2012.	1.2	48
104	Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008597.	1.6	19
105	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF. <i>Journal of the American Heart Association</i> , 2021, 10, e021494.	1.6	13
106	Trends in Anticoagulation Prescription Spending Among Medicare Part D and Medicaid Beneficiaries Between 2014 and 2019. <i>Journal of the American Heart Association</i> , 2021, 10, e022644.	1.6	10
107	Guideline based eligibility for primary prevention statin therapy â€“ Insights from the North India ST-elevation myocardial infarction registry (NORIN-STEMI). <i>Journal of Clinical Lipidology</i> , 2021, , .	0.6	4
108	Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 356-363.	1.4	19



#	ARTICLE	IF	CITATIONS
109	Trends in Aggregate Use and Associated Expenditures of Antihyperglycemic Therapies Among US Medicare Beneficiaries Between 2012 and 2017. <i>JAMA Internal Medicine</i> , 2020, 180, 141.	2.6	17
110	Longitudinal trajectories of hospital performance across targeted cardiovascular conditions in the USA. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2020, 6, 62-71.	1.8	3
111	Assessing the quality of reporting of harms in randomized controlled trials published in high impact cardiovascular journals. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2020, 6, 177-179.	1.8	3
112	Left atrial function in heart failure with preserved ejection fraction: a systematic review and meta-analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 472-485.	2.9	71
113	Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes. <i>JAMA Network Open</i> , 2020, 3, e1918962.	2.8	152
114	Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e012797.	1.6	28
115	Temporal Trends in Racial Differences in 30-Day Readmission and Mortality Rates After Acute Myocardial Infarction Among Medicare Beneficiaries. <i>JAMA Cardiology</i> , 2020, 5, 136.	3.0	33
116	How Do SGLT-2 Inhibitors Work to Prevent Heart Failure?. <i>JACC: Heart Failure</i> , 2020, 8, 67-69.	1.9	5
117	Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure. <i>Circulation</i> , 2020, 141, 352-361.	1.6	335
118	Transforming the interpretation of significance in heart failure trials. <i>European Journal of Heart Failure</i> , 2020, 22, 177-180.	2.9	2
119	Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared With Valsartan in HFpEF. <i>Journal of the American College of Cardiology</i> , 2020, 75, 245-254.	1.2	88
120	Contemporary Patterns of Medicare and Medicaid Utilization and Associated Spending on Sacubitril/Valsartan and Ivabradine in Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 336.	3.0	16
121	Gender differences in industry payments among cardiologists. <i>American Heart Journal</i> , 2020, 223, 123-131.	1.2	16
122	Angiotensinâ€“neprilysin inhibition in <i>de novo</i> heart failure â€“ starting off strong. <i>European Journal of Heart Failure</i> , 2020, 22, 313-314.	2.9	2
123	Diagnosing heart failure with preserved ejection fraction in 2019: the search for a gold standard. <i>European Journal of Heart Failure</i> , 2020, 22, 422-424.	2.9	9
124	Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause. <i>JACC: Heart Failure</i> , 2020, 8, 844-855.	1.9	56
125	Sacubitril/Valsartan. <i>JACC: Heart Failure</i> , 2020, 8, 800-810.	1.9	64
126	Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019. <i>Heart Failure Clinics</i> , 2020, 16, 433-440.	1.0	4



#	ARTICLE	IF	CITATIONS
127	What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?. Current Diabetes Reports, 2020, 20, 63.	1.7	4
128	Quantifying the Impact of Care Fragmentation on Outcomes After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2020, 128, 113-119.	0.7	0
129	Conduct of Clinical Trials in the Era of COVID-19. Journal of the American College of Cardiology, 2020, 76, 2368-2378.	1.2	35
130	Citizenship Status and Cardiothoracic Organ Transplantation in the United States. Circulation: Heart Failure, 2020, 13, e007788.	1.6	4
131	Angiotensin receptor–nepriylsin inhibition in heart failure with preserved ejection fraction: lessons from <sc>PARAGON&lt;/sc>. European Journal of Heart Failure, 2020, 22, 1525-1530.	2.9	3
132	Intensive vs. standard blood pressure control and vascular procedures: insights from the Systolic Blood Pressure Intervention Trial (SPRINT). European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 7, e35-e37.	1.4	1
133	Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes. Current Opinion in Cardiology, 2020, 35, 517-523.	0.8	2
134	Extensive Arterial Thrombosis in Covid-19. American Journal of Cardiology, 2020, 134, 148-149.	0.7	4
135	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. Circulation, 2020, 142, 1205-1218.	1.6	63
136	Medicaid Expansion and Utilization of Antihyperglycemic Therapies. Diabetes Care, 2020, 43, 2684-2690.	4.3	13
137	Temporal Trends in Heart Failure Incidence Among Medicare Beneficiaries Across Risk Factor Strata, 2011 to 2016. JAMA Network Open, 2020, 3, e2022190.	2.8	38
138	Discovery and care innovation amidst a pandemic. European Journal of Heart Failure, 2020, 22, 2202-2204.	2.9	0
139	Assessment of Heterogeneity in Heart Failure–Related Meta-Analyses. Circulation: Heart Failure, 2020, 13, e007070.	1.6	6
140	Prognostic implications of left ventricular hypertrophy diagnosed on electrocardiogram vs echocardiography. Journal of Clinical Hypertension, 2020, 22, 1647-1658.	1.0	15
141	Reply. Journal of the American College of Cardiology, 2020, 76, 2574-2575.	1.2	1
142	Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency. Journal of the American College of Cardiology, 2020, 76, 2517-2521.	1.2	10
143	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2020, 13, e006758.	1.6	8
144	Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic. Journal of the American College of Cardiology, 2020, 76, 280-288.	1.2	259

#	ARTICLE	IF	CITATIONS
145	Myocardial Infarction in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 618-626.	1.9	17
146	Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2524.	3.8	121
147	Using antimatter to uncover what matters: metformin effects on myocardial efficiency in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1638-1640.	2.9	0
148	Temporal Trends in Prevalence and Prognostic Implications of Comorbidities Among Patients With Acute Decompensated Heart Failure. <i>Circulation</i> , 2020, 142, 230-243.	1.6	59
149	Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial. <i>Diabetes Care</i> , 2020, 43, 1920-1928.	4.3	35
150	Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease. <i>JAMA Cardiology</i> , 2020, 5, 1182.	3.0	59
151	Application of Diagnostic Algorithms for Heart Failure With Preserved Ejection Fraction to the Community. <i>JACC: Heart Failure</i> , 2020, 8, 640-653.	1.9	65
152	Orphan Drug Development in Cardiovascular Medicine. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006509.	0.9	2
153	Natriuretic Peptides as Inclusion Criteria in Clinical Trials. <i>JACC: Heart Failure</i> , 2020, 8, 347-358.	1.9	53
154	Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1644-1656.	1.2	46
155	Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials. <i>JAMA Cardiology</i> , 2020, 5, 714.	3.0	76
156	Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. <i>New England Journal of Medicine</i> , 2020, 382, 1653-1659.	13.9	1,732
157	Effects of Sacubitril/Valsartan on N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 372-381.	1.9	53
158	Training the Next Generation of Cardiometabolic Specialists. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1233-1237.	1.2	9
159	Response to Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> 2019;42:2298-2306. <i>Diabetes Care</i> , 2020, 43, e26-e27.	4.3	2
160	Economic Burden Associated With Extended-Release vs Immediate-Release Drug Formulations Among Medicare Part D and Medicaid Beneficiaries. <i>JAMA Network Open</i> , 2020, 3, e200181.	2.8	7
161	Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006623.	1.6	24
162	Performance in Federal Value-Based Programs of Hospitals Recognized by the American Heart Association and American College of Cardiology for High-Quality Heart Failure and Acute Myocardial Infarction Care. <i>JAMA Cardiology</i> , 2020, 5, 515.	3.0	15

#	ARTICLE	IF	CITATIONS
163	Assessment of Long-term Benefit of Intensive Blood Pressure Control on Residual Life Span. <i>JAMA Cardiology</i> , 2020, 5, 576.	3.0	28
164	Growing Mismatch Between Evidence Generation and Implementation in Heart Failure. <i>American Journal of Medicine</i> , 2020, 133, 525-527.	0.6	6
165	Running thin: implications of a heparin shortage. <i>Lancet, The</i> , 2020, 395, 534-536.	6.3	20
166	Marijuana Use in Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2020, 75, 320-332.	1.2	91
167	Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006638.	1.6	12
168	Thirty-Day Nonindex Readmissions and Clinical Outcomes After Cardiac Surgery. <i>Annals of Thoracic Surgery</i> , 2020, 110, 484-491.	0.7	13
169	Contemporary Trends in Prescription of Dipeptidyl Peptidase-4 Inhibitors in the Context of US Food and Drug Administration Warnings of Heart Failure Risk. <i>American Journal of Cardiology</i> , 2020, 125, 1577-1581.	0.7	2
170	A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. <i>European Heart Journal</i> , 2020, 41, 2356-2362.	1.0	38
171	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2020, 7, 3298-3309.	1.4	76
172	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF. <i>JACC: Heart Failure</i> , 2020, 8, 469-480.	1.9	47
173	Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. <i>Lancet, The</i> , 2020, 396, 121-128.	6.3	376
174	Angioedema in COVID-19. <i>European Heart Journal</i> , 2020, 41, 3283-3284.	1.0	21
175	Cardio-Renal-Metabolic Care Models. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e007264.	0.9	25
176	Amyloidosis and 30-Day Outcomes Among Patients With Heart Failure. <i>JACC: CardioOncology</i> , 2020, 2, 710-718.	1.7	5
177	The First 4 Years of Postmarketing Safety Surveillance Related to the MitraClip Device: A United States Food and Drug Administration MAUDE Experience. <i>Journal of Invasive Cardiology</i> , 2020, 32, E130-E132.	0.4	7
178	Dying is not what it used to be! Impact of evolving epidemiology and treatment on mode of death in heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1267-1269.	2.9	3
179	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 862-874.	1.9	77
180	Application of the H <sub>2</sub> FPEF score to a global clinical trial of patients with heart failure with preserved ejection fraction: the TOPCAT trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1288-1291.	2.9	18

#	ARTICLE	IF	CITATIONS
181	Does dual vs. triple antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation lower the risk of bleeding at the cost of increased risk of ischemic events?. <i>IJC Heart and Vasculature</i> , 2019, 24, 100404.	0.6	0
182	Implications of Specialist Density for Diabetes Care in the United States. <i>JAMA Cardiology</i> , 2019, 4, 1174.	3.0	18
183	Incorporation of Biomarkers Into Risk Assessment for Allocation of Antihypertensive Medication According to the 2017 ACC/AHA High Blood Pressure Guideline. <i>Circulation</i> , 2019, 140, 2076-2088.	1.6	49
184	Preventing and Treating Heart Failure with Sodium-Glucose Co-Transporter 2 Inhibitors. <i>American Journal of Cardiology</i> , 2019, 124, S20-S27.	0.7	26
185	Design and rationale of the North Indian STâ€œSegment Elevation Myocardial Infarction Registry: A prospective cohort study. <i>Clinical Cardiology</i> , 2019, 42, 1140-1146.	0.7	9
186	<i>De novo</i> heart failure: where the journey begins. <i>European Journal of Heart Failure</i> , 2019, 21, 1245-1247.	2.9	2
187	Electrocardiography and left ventricular function: looking beyond hypertrophy. <i>Hypertension Research</i> , 2019, 42, 580-582.	1.5	0
188	Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2019, 140, 1369-1379.	1.6	74
189	Adoption of hepatitis C virusâ€œinfected donor hearts: A â€œmiddle childâ€œno more. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 918-919.	0.3	2
190	Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists. <i>JACC: Heart Failure</i> , 2019, 7, 169-172.	1.9	64
191	Body Mass Index, Intensive Blood Pressure Management, and Cardiovascular Events in the SPRINT Trial. <i>American Journal of Medicine</i> , 2019, 132, 840-846.	0.6	18
192	Utility of the Cardiovascular Physical Examination and Impact of Spironolactone in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2019, 12, e006125.	1.6	21
193	A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. <i>European Heart Journal</i> , 2019, 40, 3593-3602.	1.0	69
194	The rise and fall of aspirin in the primary prevention of cardiovascular disease. <i>Lancet, The</i> , 2019, 393, 2155-2167.	6.3	140
195	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2365-2383.	1.2	327
196	Post-transplant outcome in patients bridged to transplant with temporary mechanical circulatory support devices. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 858-869.	0.3	85
197	Prevalence of Apparent Treatment-Resistant Hypertension in the United States According to the 2017 High Blood Pressure Guideline. <i>Mayo Clinic Proceedings</i> , 2019, 94, 776-782.	1.4	19
198	Premature Ticagrelor Discontinuation inâ€œSecondary Prevention of Atheroscleroticâ€œCVD. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2454-2464.	1.2	47

#	ARTICLE	IF	CITATIONS
199	Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis. <i>PLoS Medicine</i> , 2019, 16, e1002797.	3.9	36
200	Association of the New Peer Groupâ€“Stratified Method With the Reclassification of Penalty Status in the Hospital Readmission Reduction Program. <i>JAMA Network Open</i> , 2019, 2, e192987.	2.8	42
201	Anticoagulation Strategies in Patients With Cancer. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1336-1349.	1.2	121
202	B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1264-1272.	1.2	139
203	Prescription of Glucagon-Like Peptide-1 Receptor Agonists by Cardiologists. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1596-1598.	1.2	38
204	Misclassification of Myocardial Injury as Myocardial Infarction. <i>JAMA Cardiology</i> , 2019, 4, 460.	3.0	80
205	Screening and Management of Depression in Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1827-1845.	1.2	182
206	Wake Forest University long-term follow-up of type 2 myocardial infarction: The Wake-Up T2MI Registry. <i>Clinical Cardiology</i> , 2019, 42, 592-604.	0.7	5
207	Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial. <i>Resuscitation</i> , 2019, 137, 205-212.	1.3	31
208	Organ Donation and Drug Intoxication-Related Deaths in the United States. <i>New England Journal of Medicine</i> , 2019, 380, 597-599.	13.9	12
209	Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial). <i>American Journal of Cardiology</i> , 2019, 123, 1660-1666.	0.7	5
210	Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> , 2019, 42, 2298-2306.	4.3	157
211	Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration. <i>Current Diabetes Reports</i> , 2019, 19, 157.	1.7	7
212	Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 1022-1028.	1.9	6
213	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 2108-2118.	1.6	22
214	Emerging Trends in Financing of Adult Heart Transplantation in the United States. <i>JACC: Heart Failure</i> , 2019, 7, 56-62.	1.9	12
215	Surprise, surprise: improving the referral pathway to palliative care interventions in advanced heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 235-237.	2.9	10
216	Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. <i>JACC: Heart Failure</i> , 2019, 7, 1-12.	1.9	109

#	ARTICLE	IF	CITATIONS
217	Relation of Serum and Urine Renal Biomarkers to Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes (From the EXAMINE Trial). <i>American Journal of Cardiology</i> , 2019, 123, 382-391.	0.7	12
218	Thirty-Day Readmissions After Hospitalization for Hypertensive Emergency. <i>Hypertension</i> , 2019, 73, 60-67.	1.3	26
219	Pulse Pressure, Cardiovascular Events, and Intensive Blood-Pressure Lowering in the Systolic Blood Pressure Intervention Trial (SPRINT). <i>American Journal of Medicine</i> , 2019, 132, 733-739.	0.6	21
220	Sudden Death in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 653-661.	1.9	56
221	Expanding the global borders of heart failure: the SHOP and PEOPLE studies. <i>European Heart Journal</i> , 2018, 39, 1781-1783.	1.0	4
222	Baseline Blood Pressure, the 2017 ACC/AHA High Blood Pressure Guidelines, and Long-Term Cardiovascular Risk in SPRINT. <i>American Journal of Medicine</i> , 2018, 131, 956-960.	0.6	27
223	Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 398-405.	2.2	28
224	Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. <i>Current Heart Failure Reports</i> , 2018, 15, 10-16.	1.3	6
225	Reply: Intersection of fasting plasma glucose, adverse cardiac remodeling, and clinical outcomes. <i>International Journal of Cardiology</i> , 2018, 252, 214-215.	0.8	1
226	Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 123-131.	0.6	0
227	Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 564-569.	1.9	43
228	Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials. <i>American Journal of Medicine</i> , 2018, 131, 575-577.	0.6	37
229	Availability and Use of Shared Data From Cardiometabolic Clinical Trials. <i>Circulation</i> , 2018, 137, 938-947.	1.6	17
230	Moving Beyond the Hospital. <i>Circulation</i> , 2018, 138, 2169-2171.	1.6	1
231	Targeting sudden death in heart failure with preserved ejection fraction: promise or pipedream?. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 875-877.	0.6	1
232	Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 975-982.	1.9	111
233	Developing evidence-based and accountable health policy in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1653-1656.	2.9	4
234	High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. <i>Journal of the American Heart Association</i> , 2018, 7, e010364.	1.6	22

#	ARTICLE	IF	CITATIONS
235	Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. Journal of the American College of Cardiology, 2018, 72, 3370-3372.	1.2	102
236	Fifteen-Year Trends in Management and Outcomes of Non-ST-Segment Elevation Myocardial Infarction Among Black and White Patients: The ARIC Community Surveillance Study, 2000-2014. Journal of the American Heart Association, 2018, 7, e010203.	1.6	32
237	Optimizing the Detection of Left Ventricular Thrombus Following Acute Myocardial Infarction in the Current Era—Reply. JAMA Cardiology, 2018, 3, 1129.	3.0	1
238	The Reply. American Journal of Medicine, 2018, 131, e389-e390.	0.6	0
239	The Drug-Intoxication Epidemic and Solid-Organ Transplantation. New England Journal of Medicine, 2018, 378, 1943-1945.	13.9	68
240	The Reply. American Journal of Medicine, 2018, 131, e263.	0.6	0
241	Epirubicin and long-term heart failure risk in breast cancer survivors. European Journal of Heart Failure, 2018, 20, 1454-1456.	2.9	4
242	The Current Landscape of Atrial Fibrillation and Atrial Flutter Clinical Trials. JACC: Clinical Electrophysiology, 2018, 4, 944-954.	1.3	5
243	Pectus Excavatum and Right Ventricular Compression in a Young Athlete with Syncope. American Journal of Medicine, 2018, 131, e451-e453.	0.6	1
244	Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38	0.7	6
245	Oral Anticoagulation in Patients With Liver Disease. Journal of the American College of Cardiology, 2018, 71, 2162-2175.	1.2	127
246	Left Ventricular Thrombus After Acute Myocardial Infarction. JAMA Cardiology, 2018, 3, 642.	3.0	171
247	Navigating Data Sharing in Cardiology From a Trainee's Perspective. Journal of the American College of Cardiology, 2018, 71, 2075-2078.	1.2	0
248	Type 2 Myocardial Infarction and the Hospital Readmission Reduction Program. Journal of the American College of Cardiology, 2018, 72, 1166-1170.	1.2	16
249	Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction. JAMA Cardiology, 2018, 3, 1000.	3.0	41
250	Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials. JAMA Cardiology, 2018, 3, 1011.	3.0	146
251	The Reply. American Journal of Medicine, 2018, 131, e267-e268.	0.6	0
252	Type 2 Myocardial Infarction—Diagnosis, Prognosis, and Treatment. JAMA - Journal of the American Medical Association, 2018, 320, 433.	3.8	51



#	ARTICLE	IF	CITATIONS
253	Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. <i>International Journal of Cardiology</i> , 2017, 230, 301-303.	0.8	9
254	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 176-185.	1.2	47
255	Gastrointestinal Bleeding With Oral Anticoagulation: Understanding the Scope of the Problem. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 691-693.	2.4	22
256	Mode of Death in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 69, 556-569.	1.2	193
257	Prognostic implications of fasting plasma glucose in subjects with echocardiographic abnormalities. <i>International Journal of Cardiology</i> , 2017, 241, 423-429.	0.8	9
258	Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 682-685.	2.9	39
259	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors. <i>JAMA Cardiology</i> , 2017, 2, 127.	3.0	36
260	Cangrelor Use Since FDA Approval. <i>Journal of the American College of Cardiology</i> , 2017, 69, 463-464.	1.2	20
261	Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the <sc>ASTRONAUT</sc> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 552-562.	2.9	23
262	Preparing Fellows for Precision Cardiology. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1675-1679.	1.2	4
263	Safety and Tolerability of Transitioning from Cangrelor to Ticagrelor in Patients Who Underwent Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2017, 120, 359-361.	0.7	10
264	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302	0.7	12
265	Impact of Site Selection and Study Conduct on Outcomes in Global Clinical Trials. <i>Current Heart Failure Reports</i> , 2017, 14, 203-209.	1.3	3
266	Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	47
267	Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	20
268	Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1648-1659.	0.8	18
269	Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. <i>Cardiac Failure Review</i> , 2017, 3, 122.	1.2	27
270	Coronary stenting approaches in the treatment of chronic total occlusion. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 673-679.	0.6	1

#	ARTICLE	IF	CITATIONS
271	Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?. <i>European Journal of Heart Failure</i> , 2016, 18, 128-132.	2.9	9
272	Serum chloride in heart failure: a salty prognosis. <i>European Journal of Heart Failure</i> , 2016, 18, 669-671.	2.9	12
273	Cardiovascular clinical trials with noninferiority or equivalence designs from 2001 to 2012. <i>International Journal of Cardiology</i> , 2016, 214, 16-18.	0.8	2
274	Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1661-1671.	1.2	69
275	Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. <i>American Journal of Medicine</i> , 2016, 129, 1002-1005.	0.6	32
276	Stroke prevention in heart failure and sinus rhythm: where do we go from here?. <i>European Journal of Heart Failure</i> , 2016, 18, 1267-1269.	2.9	1
277	Transforming Drug Development in Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	8
278	One-Year Outcomes After Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Varying Quantities of Coronary Artery Calcium (from a 13-Year Registry). <i>American Journal of Cardiology</i> , 2016, 118, 1111-1116.	0.7	2
279	Angiotensin-Neprilysin Inhibition as a Paradigm for All?. <i>Current Cardiology Reports</i> , 2016, 18, 115.	1.3	9
280	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	10
281	Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?. <i>Heart Failure Reviews</i> , 2016, 21, 455-462.	1.7	26
282	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2016, 117, 1144-1150.	0.7	23
283	Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials. <i>American Journal of Cardiology</i> , 2016, 117, 1845-1850.	0.7	11
284	Trends in Heart Failure Clinical Trials From 2001 to 2012. <i>Journal of Cardiac Failure</i> , 2016, 22, 171-179.	0.7	22
285	Simultaneous Platelet P2Y <sub>12</sub> and P2Y <sub>1</sub> ADP Receptor Blockade. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 427-428.	1.1	5
286	Risk of Cardiovascular Hospitalizations from Exposure to Coarse Particulate Matter (PM <sub>10</sub> ) Below the European Union Safety Threshold. <i>American Journal of Cardiology</i> , 2016, 117, 1231-1235.	0.7	38
287	Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016, 117, 340-346.	0.7	12
288	A Triad of Linezolid Toxicity: Hypoglycemia, Lactic Acidosis, and Acute Pancreatitis. <i>Baylor University Medical Center Proceedings</i> , 2015, 28, 466-468.	0.2	16

#	ARTICLE	IF	CITATIONS
289	Metastatic Pancreatic Neuroendocrine Tumor with Ectopic Adrenocorticotrophic Hormone Production. Baylor University Medical Center Proceedings, 2015, 28, 46-49.	0.2	4
290	Large-Volume Barium Aspiration. Baylor University Medical Center Proceedings, 2015, 28, 183-184.	0.2	8
291	Contemporary Cardiovascular Device Clinical Trials (Trends and Patterns 2001 to 2012). American Journal of Cardiology, 2015, 116, 307-312.	0.7	2
292	Changes in Serum Potassium Levels During Hospitalization in Patients With Worsening Heart Failure and Reduced Ejection Fraction (from the EVEREST Trial). American Journal of Cardiology, 2015, 115, 790-796.	0.7	37
293	The vulnerable phase after hospitalization for heart failure. Nature Reviews Cardiology, 2015, 12, 220-229.	6.1	238
294	Relation between ticagrelor response and levels of circulating reticulated platelets in patients with non-ST elevation acute coronary syndromes. Journal of Thrombosis and Thrombolysis, 2015, 40, 211-217.	1.0	21
295	Contemporary Drug Development in Heart Failure. Circulation: Heart Failure, 2015, 8, 826-831.	1.6	34
296	Ping-Pong Gaze. New England Journal of Medicine, 2015, 372, e34.	13.9	3
297	Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. Expert Review of Cardiovascular Therapy, 2015, 13, 799-809.	0.6	10
298	Prognostic scores in heart failure – Critical appraisal and practical use. International Journal of Cardiology, 2015, 188, 1-9.	0.8	45
299	Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. Heart Failure Reviews, 2015, 20, 393-400.	1.7	3
300	Revisiting the Clopidogrel-Proton Pump Inhibitor Interaction. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	3
301	Hospitalized Heart Failure in the United States. Heart Failure Clinics, 2015, 11, 591-601.	1.0	3
302	A roadmap to inpatient heart failure management. Journal of Cardiology, 2015, 65, 26-31.	0.8	4
303	Sudden Flare of Rheumatoid Arthritis Associated with Newly Diagnosed Atrial Flutter. Baylor University Medical Center Proceedings, 2014, 27, 233-234.	0.2	0
304	Acute Lymphocytic Leukemia with Superimposed Invasive Aspergillosis and Pneumopericardium Successfully Treated with Voriconazole. Baylor University Medical Center Proceedings, 2014, 27, 250-252.	0.2	0
305	Torus Palatinus. Baylor University Medical Center Proceedings, 2014, 27, 259-259.	0.2	2
306	Effect of intensive glycaemic control on endothelial progenitor cells in patients with long-standing uncontrolled type 2 diabetes. European Journal of Preventive Cardiology, 2014, 21, 1153-1162.	0.8	16

#	ARTICLE	IF	CITATIONS
307	Hemoconcentration-guided Diuresis in Heart Failure. American Journal of Medicine, 2014, 127, 1154-1159.	0.6	43
308	Dual Antiplatelet Therapy After Stent Implantation. JAMA - Journal of the American Medical Association, 2014, 311, 1446.	3.8	1
309	Modern Drug Development. JAMA - Journal of the American Medical Association, 2014, 312, 2619.	3.8	5
310	Influence of Chronic Kidney Disease on Warfarin Therapy for Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2014, 311, 2541.	3.8	0
311	In Reply to Loh and Lin. Academic Medicine, 2014, 89, 530.	0.8	1
312	Coronary Artery Disease in Patients with Heart Failure: Incidental, Coincidental, or a Target for Therapy?. American Journal of Medicine, 2014, 127, 574-578.	0.6	2
313	Response to Prasugrel and Levels of Circulating Reticulated Platelets in Patients With ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2014, 63, 513-517.	1.2	80
314	Lipids, statins, and clinical outcomes in heart failure: rethinking the data. Heart Failure Reviews, 2014, 19, 695-698.	1.7	4
315	The Global Health and Economic Burden of Hospitalizations for Heart Failure. Journal of the American College of Cardiology, 2014, 63, 1123-1133.	1.2	1,640
316	Relation of Serum Uric Acid Levels and Outcomes Among Patients Hospitalized for Worsening Heart Failure With Reduced Ejection Fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure) Trial. JAMA, 2014, 311, 1446.	1.2	1,640
317	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2014, 7, 401-408.	1.6	34
318	Mineralocorticoid Receptor Antagonist Use in Hospitalized Patients With Heart Failure, Reduced Ejection Fraction, and Diabetes Mellitus (from the EVEREST Trial). American Journal of Cardiology, 2014, 114, 743-750.	0.7	8
319	The Use of Digoxin in Patients With Worsening Chronic Heart Failure. Journal of the American College of Cardiology, 2014, 63, 1823-1832.	1.2	88
320	Death Due to Munchausen Syndrome: A Case of Idiopathic Recurrent Right Ventricular Failure and a Review of the Literature. Psychosomatics, 2014, 55, 668-672.	2.5	15
321	Designing effective drug and device development programs for hospitalized heart failure: A proposal for pretrial registries. American Heart Journal, 2014, 168, 142-149.	1.2	34
322	Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Failure Reviews, 2014, 19, 135-152.	1.7	48
323	Rehospitalization for Heart Failure. Journal of the American College of Cardiology, 2013, 61, 391-403.	1.2	582
324	The immunological axis in heart failure: importance of the leukocyte differential. Heart Failure Reviews, 2013, 18, 835-845.	1.7	54

#	ARTICLE	IF	CITATIONS
325	Progress or lack of progress in hospitalized heart failure. Expert Review of Cardiovascular Therapy, 2013, 11, 1079-1083.	0.6	3
326	The Prognostic Significance of Heart Rate in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in Sinus Rhythm. JACC: Heart Failure, 2013, 1, 488-496.	1.9	58
327	Epidemiology of Hospitalized Heart Failure. Heart Failure Clinics, 2013, 9, 271-276.	1.0	13
328	Evaluative Framework for Phase II Studies in Patients With Heart Failure and Preserved Ejection Fraction. JACC: Heart Failure, 2013, 1, 123-126.	1.9	8
329	Relationship Between Clinical Trial Site Enrollment With Participant Characteristics, Protocol Completion, and Outcomes. Journal of the American College of Cardiology, 2013, 61, 571-579.	1.2	58
330	Classification of Patients Hospitalized for Heart Failure. Heart Failure Clinics, 2013, 9, 277-283.	1.0	3
331	Drug Therapy to Reduce Early Readmission Risk in Heart Failure. JACC: Heart Failure, 2013, 1, 361-364.	1.9	10
332	Relation of Serum Magnesium Levels and Postdischarge Outcomes in Patients Hospitalized for Heart Failure (from the EVEREST Trial). American Journal of Cardiology, 2013, 112, 1763-1769.	0.7	8
333	Expanding the Scope of the "Polypill" to Heart Failure. Journal of Cardiac Failure, 2013, 19, 540-541.	0.7	5
334	Anticoagulation in heart failure: current status and future direction. Heart Failure Reviews, 2013, 18, 797-813.	1.7	28
335	The disconnect between phase II and phase III trials of drugs for heart failure. Nature Reviews Cardiology, 2013, 10, 85-97.	6.1	69
336	Thirty-Day Readmissions. JAMA - Journal of the American Medical Association, 2013, 309, 345.	3.8	102
337	Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment. Journal of Cardiovascular Medicine, 2012, 13, 415-422.	0.6	29
338	Predictive Value of Low Relative Lymphocyte Count in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2012, 5, 750-758.	1.6	89
339	Relation of Body Mass Index to Late Survival After Valvular Heart Surgery. American Journal of Cardiology, 2012, 110, 1667-1678.	0.7	39
340	Midterm Benefits of Preoperative Statin Therapy in Patients Undergoing Isolated Valve Surgery. Annals of Thoracic Surgery, 2012, 93, 1881-1887.	0.7	9